investing

Coronavirus Drugs Already in the Pipeline

It's not just chloroquine. Other existing medicines are being brought to bear against COVID-19. We look at what drugs have promise against COVID-19, and when they will get here.

What drugs will be available to treat COVID-19? Here's a quick rundown and a timeline for when to expect them. Note that these drugs have not been proven yet in trials of patients suffering from the novel coronavirus, and as such do not have official FDA approval, but they may still be helpful.

A lot of attention has been paid to existing antimalarials (in the chloroquine family) or flu drugs (favipiravir)

The antimalarials are in short supply, but production is ramping up. Mylan (MYL) and Teva Pharmaceuticals (TEVA) plan to jump-start production of hydroxychloroquine, which is also approved for treating lupus or rheumatoid arthritis. Teva says it will donate 6 million doses of hydroxychloroquine sulfate tablets tablets through wholesalers to hospitals by March 31. We expect them to be widely available in mid-April.

Remdesivir has been studied for years as an experimental antiviral, most recently for its potential against Ebola. Doctors were throwing it against COVID-19 in a "try something" approach, to the point that demand led its manufacturer, Gilead (GILD), to limit its used to clinical trials. Six large studies are ongoing. The first should report results on April 3, the second in mid-April, and two more in May.

One side effect of COVID-19 is a so-called "cytokine storm," in which the virus causes the immune system to overreact. Actemra by Roche (RHHBY) and Kevzara, by Sanofi (SNY) and Regeneron (REGN), are existing arthritis drugs which may also be able to counter a cytokine storm. Currently available, but starting testing for COVID-19 use.

Convalescent plasma, blood plasma from patients who have recovered from the virus, with their antibodies in it. Still in research, availability at least nine months away.

Artificial antibodies, which are similar to blood plasma but more consistent. Trials should begin in early summer, availability possible in the early fall. Companies working on this idea: Regeneron, Eli Lilly (LLY) with AbCellera, Vir Biotechnology (VIR), and Biogen (BIIB).

Most Popular

Your Guide to Roth Conversions
Special Report
Tax Breaks

Your Guide to Roth Conversions

A Kiplinger Special Report
February 25, 2021
The 12 Best Tech Stocks to Buy for 2022
tech stocks

The 12 Best Tech Stocks to Buy for 2022

The best tech-sector picks for the year to come include plays on some of the most exciting emergent technologies, as well as several old-guard mega-ca…
January 3, 2022
How to Know When You Can Retire
retirement

How to Know When You Can Retire

You’ve scrimped and saved, but are you really ready to retire? Here are some helpful calculations that could help you decide whether you can actually …
January 5, 2022

Recommended

Is the Stock Market Closed on MLK Day?
Markets

Is the Stock Market Closed on MLK Day?

Both the stock markets and bond markets will have Monday off as the nation honors civil rights leader Martin Luther King Jr.
January 15, 2022
Stock Market Holidays in 2022
Markets

Stock Market Holidays in 2022

Is the stock market open today? Take a look at which days the NYSE, Nasdaq and bond markets take off in 2022.
January 14, 2022
Your Child Care Tax Credit May Be Bigger on Your 2021 Tax Return
Tax Breaks

Your Child Care Tax Credit May Be Bigger on Your 2021 Tax Return

Many families with young children will get a bigger tax credit for last year's childcare expenses. And more families will qualify for the credit, too.
January 13, 2022
4 Tips on How to Build a Better Bond Position
bonds

4 Tips on How to Build a Better Bond Position

In a world where stock markets keep setting records, bonds look quite dull in comparison. But don’t give up on them! Polish up your bond portfolio usi…
January 12, 2022